Does the manufacturer offer customization?

Yes, the company provides both OEM and ODM services with a team of 20 R&D engineers.

What are the main advantages over yeast?

It uses modified montmorillonite that reduces impurities by 90% and increases adsorption capacity 2-3 times compared to yeast.

Veterinary Drug Anti-Mycotoxin Toxin Binder Premix and Water Soluble Powder

Name: Veterinary Drug Anti-Mycotoxin Toxin Binder Premix and Water Soluble Powder
Brand: Henan Muxiang Biological Co., Ltd.
SKU: 1943543172

Henan, ChinaHenan Muxiang Biological Co., Ltd.

US$0.88

1,000 kg

Sample price:US$1.80/kg.Request sample

Product profile

Customization

Available

Varieties

General Disease Prevention Medicine

Component

Chemical Synthetic Drugs

Model NO.

1kg/bag; 25kg/bag

Type

The First Class

Pharmacodynamic Influential Factors

Combined Medication

Storage Method

Light Proof

Transport Package

Carton, Bucket

Specification

1kg/bag; 25kg/bag

Trademark

MOOSUN

Origin

China

HS Code

3004909090

Production Capacity

1500/Year

Key features

Enhanced Adsorption: Modified montmorillonite reduces impurities by 90%, increasing adsorption capacity 2-3 times.

Immunity Improvement: Dew oligosaccharides release immunosuppression and improve animal immunity.

Liver Protection: Cracks mycotoxins in the body and protects animal livers from damage.

Broad Applicability: Safe and effective for all ages of poultry and livestock.

OEM/ODM Support: Manufacturer offers both OEM and ODM services with 20 R&D engineers.

Flexible Packaging: Available in 1kg/bag and 25kg/bag options for varied needs.

Company profile

Henan Muxiang Biological Co., Ltd.

Henan, China

CertifiedBusiness Type: Manufacturer/Factory & Trading Company CertifiedR&D Capacity: ODM Service Available & OEM Service AvailableExport Year: 2016-02-01 CertifiedNearest Port: Shanghai Port, Qingdao PortAverage Response Time: ≤10.10h CertifiedTerms of Payment: LC, T/T, D/P, etc.

AI-Powered supplier vetting

SummaryHenan Muxiang Biological Co., Ltd. is a China-based limited-company factory established in 2004, with 360 employees and operations in veterinary pharmaceuticals and animal-health products. The supplier reports seven pharmaceutical production lines, eight vaccine production lines, first-class production and inspection equipment, GMP management, ISO9001:2015 certification, and ISO/CNAS laboratory certification. Its R&D resources include more than 40 core personnel, over 30 of whom hold doctoral or master's degrees, while 21–30 quality-control staff are reported. The company exports to multiple global regions, has self-operated import and export rights, and states a one-month order-fulfillment period in both peak and off-peak seasons. Evidence supports capabilities in certification, innovation, production, and international operations. However, the provided information does not sufficiently establish after-sales service performance, financial credibility, customization execution, or specific customer cases.

Supplier typeThe supplier is identified as a limited company and a factory in the manufacturing industry, with its operating location in Henan, China. This indicates a direct manufacturing entity rather than only a trading or intermediary business.

CertificationsThe supplier reports a systematic GMP management system, ISO/CNAS laboratory international certification, and an ISO9001:2015 certificate. These stated certifications and quality systems provide explicit evidence of formal quality-management capability.

R&D capabilityThe supplier reports more than 40 core R&D personnel, including over 30 doctors or master's degree graduates, 20 years of preparation-technology experience among R&D engineers, and advanced R&D platforms such as a National Enterprise Technology Center, National Postdoctoral Research Station, and Academician Workstation. It also reports improving herbal active-ingredient extraction by more than 30% versus a traditional process, supporting a strong stated innovation profile.

Production capacityThe supplier reports seven pharmaceutical production lines and eight vaccine production lines, first-class production and inspection equipment, six production lines in a separate operational data field, and one-month order fulfillment in both peak and off-peak seasons. Although the line-count figures are not fully consistent across the slices, the evidence clearly supports substantial pharmaceutical and vaccine manufacturing capability.